Table 2. Laboratory and microbiological findings, treatments, and outcomes of invasive infections caused by Burkholderia cepacia complex in persons who inject drugs, Hong Kong, China, 2016–2019*.

Variable	Finding
Median leukocytes, × 109 cells/L (range)	9.2 (3.94–24.7)
Median ESR, mm/h (range)	79.5 (43 to >120)
Median CRP, mg/L (range)	68 (21 to >294)
Empirical antimicrobial therapy (no. patients)	Amoxicillin/clavulanate (10); cloxacillin (3); vancomycin (2); ampicillin, cefoperazone/sulbactam, gentamicin, piperacillin/tazobactam (1)
Definitive antimicrobial therapy (no. patients)	Trimethoprim/sulfamethoxazole (6); ceftazidime (5); levofloxacin (5); meropenem (2); minocycline, piperacillin/tazobactam (1)
Median duration of antimicrobial therapy (range), wk	6 (1–12)
Surgery (no. patients)	Vertebral disk excision (3), incision and drainage (1), spinal fusion† (3), joint arthrotomy (2), excisional arthroplasty (1)
Positive culture (no. patients)	Bone (5), blood† (4), intervertebral disk (3), abscess (2), joint fluid (1)
Median length of stay (range), d	43 (11 – 97)
Death (d after first visit)	Patient 3 (124); patient 4 (13)

*CRP, C-reactive protein; ESR, erythrocyte sedimentation rate. †Patient 2 had a relapse of Burkholderia cepacia complex infective spondylitis 5 mo after receiving meropenem and oral trimethoprim/sulfamethoxazole for 6 wk; spinal fusion was performed during the relapse episode.